NEW YORK (GenomeWeb News) – Following pricing on the BRACAnalysis and Colaris tests from Medicare contractor Noridian Administrative Services, Myriad Genetics on Friday said that total revenues and diluted EPS for fiscal 2013 are expected to be at the high end of previously issued guidance.

The Salt Lake City-based company previously guided to revenues of between $575 million and $585 million and EPS of between $1.55 and $1.58.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.